​
​

Biogen (BIIB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BIIB Stock Forecast

Biogen stock forecast is as follows: an average price target of $276.59 (represents a 77.30% upside from BIIB’s last price of $156.00) and a rating consensus of 'Buy', based on 33 wall street analysts offering a 1-year stock forecast.

BIIB Price Target

The average price target for Biogen (BIIB) is $276.59 based on 1-year price targets from 33 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $202.00. This represents a potential 77.30% upside from BIIB's last price of $156.00.

BIIB Analyst Ratings

Buy

According to 33 Wall Street analysts, Biogen's rating consensus is 'Buy'. The analyst rating breakdown for BIIB stock is 0 'Strong Buy' (0.00%), 24 'Buy' (72.73%), 9 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Biogen Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Brian SkorneyRobert W. Baird$300.00$162.8384.24%92.31%
Oct 31, 2024Jay OlsonOppenheimer$255.00$181.1840.74%63.46%
Oct 31, 2024Terence FlynnMorgan Stanley$204.00$181.1812.60%30.77%
Oct 30, 2024Christopher RaymondRaymond James$315.00$181.1873.86%101.92%
Oct 30, 2024Salveen RichterGoldman Sachs$290.00$181.1860.06%85.90%
Oct 17, 2024Evan SeigermanBMO Capital$230.00$188.1622.23%47.44%
Oct 03, 2024Ashwani VermaUBS$202.00$188.747.03%29.49%
Sep 23, 2024Laura ChicoWedbush$205.00$199.362.83%31.41%
Jul 29, 2024Brian SkorneyRobert W. Baird$294.00$212.7038.22%88.46%
Jul 26, 2024Salveen RichterGoldman Sachs$342.00$211.1761.95%119.23%
Row per page
Go to

The latest Biogen stock forecast, released on Nov 15, 2024 by Brian Skorney from Robert W. Baird, set a price target of $300.00, which represents a 84.24% increase from the stock price at the time of the forecast ($162.83), and a 92.31% increase from BIIB last price ($156.00).

Biogen Price Target by Period

1M3M12M
# Anlaysts5824
Avg Price Target$272.80$250.13$276.79
Last Closing Price$156.00$156.00$156.00
Upside/Downside74.87%60.34%77.43%

In the current month, the average price target of Biogen stock is $272.80, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 74.87% increase as opposed to Biogen's last price of $156.00. This month's average price target is up 9.06% compared to last quarter, and down -1.44% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024CitigroupNeutralNeutralInitialise
Oct 31, 2024OppenheimerOutperformOutperformHold
Oct 31, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Oct 30, 2024Piper SandlerOverweightOverweightHold
Oct 30, 2024Goldman SachsBuyBuyHold
Oct 17, 2024BMO CapitalOutperformOutperformHold
Oct 03, 2024UBSNeutralNeutralHold
Sep 24, 2024Cowen & Co.BuyBuyHold
Sep 23, 2024Wells FargoBuyBuyHold
Sep 23, 2024WedbushUnderperformUnderperformHold
Row per page
Go to

Biogen's last stock rating was published by Citigroup on Nov 13, 2024. The company gave BIIB a "Neutral" rating, the same as its previous rate.

Biogen Financial Forecast

Biogen Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$2.53B$2.46B$2.46B$2.54B$2.51B$2.59B$2.53B$2.73B$2.78B$2.77B$2.69B$2.85B$3.38B$3.68B$3.53B$3.67B$3.60B
Avg Forecast$2.51B$2.47B$2.41B$2.34B$2.41B$2.39B$2.39B$2.33B$2.42B$2.43B$2.39B$2.31B$2.47B$2.40B$2.37B$2.34B$2.45B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
High Forecast$2.61B$2.56B$2.50B$2.42B$2.50B$2.47B$2.48B$2.45B$2.50B$2.44B$2.40B$2.31B$2.56B$2.51B$2.45B$2.43B$2.54B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
Low Forecast$2.39B$2.35B$2.29B$2.22B$2.29B$2.27B$2.27B$2.26B$2.24B$2.43B$2.39B$2.31B$2.35B$2.29B$2.25B$2.23B$2.32B$2.47B$2.47B$2.50B$2.62B$2.67B$2.61B$2.65B$2.80B$3.33B$3.43B$3.42B$3.54B$3.54B
# Analysts3345452726132522272613151412122425132313131599168
Surprise %-------------1.05%1.04%1.05%1.04%1.02%1.05%1.01%1.04%1.04%1.06%1.02%1.02%1.01%1.07%1.03%1.04%1.02%

Biogen's average Quarter revenue forecast for Dec 23 based on 27 analysts is $2.47B, with a low forecast of $2.35B, and a high forecast of $2.56B. BIIB's average Quarter revenue forecast represents a -2.54% decrease compared to the company's last Quarter revenue of $2.53B (Sep 23).

Biogen EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452726132522272613151412122425132313131599168
EBITDA-------------$371.70M$708.60M$577.10M$515.10M$971.00M$1.04B$739.60M$1.01B$502.80M$168.70M$666.00M$517.60M$1.13B$2.17B$1.86B$1.87B$2.13B
Avg Forecast$936.89M$921.46M$899.01M$870.80M$899.19M$888.97M$891.28M$870.05M$900.14M$907.35M$891.66M$906.78M$919.08M$894.36M$882.12M$824.35M$1.11B$860.07M$861.72M$749.41M$912.66M$929.83M$908.92M$626.36M$974.21M$1.16B$1.19B$1.52B$1.23B$1.23B
High Forecast$971.53M$955.54M$932.25M$903.01M$932.45M$921.85M$924.24M$914.67M$933.61M$907.98M$892.96M$1.09B$952.71M$936.76M$914.75M$989.22M$1.33B$860.07M$861.72M$899.29M$912.66M$929.83M$908.92M$751.63M$974.21M$1.16B$1.19B$1.82B$1.23B$1.23B
Low Forecast$890.46M$875.81M$854.46M$827.66M$854.64M$844.92M$847.12M$844.02M$833.19M$906.72M$890.37M$725.43M$874.25M$852.15M$838.42M$659.48M$888.28M$860.07M$861.72M$599.53M$912.66M$929.83M$908.92M$501.09M$974.21M$1.16B$1.19B$1.21B$1.23B$1.23B
Surprise %-------------0.42%0.80%0.70%0.46%1.13%1.21%0.99%1.11%0.54%0.19%1.06%0.53%0.98%1.81%1.22%1.52%1.73%

27 analysts predict BIIB's average Quarter EBITDA for Dec 23 to be $919.08M, with a high of $952.71M and a low of $874.25M. This is 147.26% upper than Biogen's previous annual EBITDA (Sep 23) of $371.70M.

Biogen Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452726132522272613151412122425132313131599168
Net Income-------------$-68.10M$591.60M$387.90M$550.40M$1.13B$1.06B$221.80M$-38.20M$329.20M$448.50M$410.20M$357.90M$701.50M$1.54B$1.40B$1.44B$1.55B
Avg Forecast$617.81M$481.09M$520.73M$486.66M$563.25M$581.88M$614.07M$549.32M$500.10M$550.39M$593.52M$431.38M$464.54M$579.74M$551.00M$392.17M$403.82M$601.96M$592.38M$356.51M$492.71M$596.18M$663.72M$385.78M$699.11M$1.18B$1.17B$1.14B$1.17B$1.21B
High Forecast$647.52M$504.22M$545.77M$510.06M$590.33M$609.86M$643.59M$753.19M$593.51M$550.87M$597.02M$517.66M$567.45M$653.84M$577.49M$470.60M$484.59M$601.96M$592.38M$427.82M$492.71M$596.18M$663.72M$462.94M$699.11M$1.18B$1.17B$1.37B$1.17B$1.21B
Low Forecast$578.02M$450.10M$487.19M$455.32M$526.97M$544.40M$574.52M$307.22M$468.48M$549.91M$590.02M$345.11M$404.27M$451.88M$515.51M$313.73M$323.06M$601.96M$592.38M$285.21M$492.71M$596.18M$663.72M$308.63M$699.11M$1.18B$1.17B$915.12M$1.17B$1.21B
Surprise %--------------0.12%1.07%0.99%1.36%1.89%1.79%0.62%-0.08%0.55%0.68%1.06%0.51%0.59%1.32%1.22%1.23%1.28%

Biogen's average Quarter net income forecast for Sep 23 is $579.74M, with a range of $451.88M to $653.84M. BIIB's average Quarter net income forecast represents a -2.01% decrease compared to the company's last Quarter net income of $591.60M (Jun 23).

Biogen SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452726132522272613151412122425132313131599168
SG&A-------------$788.20M$548.00M$605.00M$632.80M$563.30M$572.60M$634.90M$787.90M$654.10M$637.30M$595.00M$806.20M$573.10M$555.10M$570.10M$664.90M$554.50M
Avg Forecast$548.23M$539.21M$526.07M$509.56M$526.18M$520.19M$521.54M$509.12M$526.73M$530.95M$521.77M$901.53M$537.81M$523.35M$516.19M$819.57M$864.13M$538.47M$539.51M$745.07M$571.40M$582.15M$569.06M$559.58M$609.94M$727.27M$748.03M$466.11M$771.61M$771.73M
High Forecast$568.51M$559.15M$545.52M$528.41M$545.63M$539.43M$540.83M$535.23M$546.32M$531.32M$522.53M$1.08B$557.49M$548.16M$535.28M$983.49M$1.04B$538.47M$539.51M$894.08M$571.40M$582.15M$569.06M$671.50M$609.94M$727.27M$748.03M$559.33M$771.61M$771.73M
Low Forecast$521.07M$512.49M$500.00M$484.31M$500.10M$494.42M$495.70M$493.89M$487.55M$530.58M$521.01M$721.22M$511.58M$498.64M$490.61M$655.66M$691.30M$538.47M$539.51M$596.05M$571.40M$582.15M$569.06M$447.67M$609.94M$727.27M$748.03M$372.89M$771.61M$771.73M
Surprise %-------------1.51%1.06%0.74%0.73%1.05%1.06%0.85%1.38%1.12%1.12%1.06%1.32%0.79%0.74%1.22%0.86%0.72%

Biogen's average Quarter SG&A projection for Dec 23 is $537.81M, based on 27 Wall Street analysts, with a range of $511.58M to $557.49M. The forecast indicates a -31.77% fall compared to BIIB last annual SG&A of $788.20M (Sep 23).

Biogen EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts3345452726132522272613151412122425132313131599168
EPS-------------$-0.47$4.09$2.69$3.82$7.86$7.25$1.51$-0.26$2.22$3.00$2.70$2.33$4.47$9.60$8.10$8.10$8.40
Avg Forecast$4.23$3.30$3.57$3.34$3.86$3.99$4.21$3.77$3.43$3.77$4.07$3.47$3.18$3.97$3.78$3.28$3.49$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
High Forecast$4.44$3.46$3.74$3.50$4.05$4.18$4.41$5.16$4.07$3.78$4.09$3.48$3.89$4.48$3.96$3.44$3.66$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
Low Forecast$3.96$3.09$3.34$3.12$3.61$3.73$3.94$2.11$3.21$3.77$4.04$3.46$2.77$3.10$3.53$3.07$3.26$4.13$4.06$4.34$3.38$4.09$4.55$4.98$4.79$8.09$8.02$7.72$8.03$8.30
Surprise %--------------0.12%1.08%0.82%1.09%1.91%1.79%0.35%-0.08%0.54%0.66%0.54%0.49%0.55%1.20%1.05%1.01%1.01%

According to 26 Wall Street analysts, Biogen's projected average Quarter EPS for Sep 23 is $3.97, with a low estimate of $3.10 and a high estimate of $4.48. This represents a -2.85% decrease compared to BIIB previous annual EPS of $4.09 (Jun 23).

Biogen Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer$24.94$44.7679.47%Hold
BIIBBiogen$156.00$276.5977.30%Buy
GSKGSK$33.35$58.0073.91%Hold
MRKMerck$97.44$128.8932.28%Buy
SNYSanofi$47.78$57.3620.05%Buy
JNJJohnson & Johnson$153.11$179.1316.99%Buy
BMYBristol-Myers Squibb Company$57.88$65.5013.17%Hold
NVSNovartis$103.09$116.3312.84%Hold
AMGNAmgen$287.87$301.814.84%Buy
ABBVAbbVie$167.76$173.303.30%Buy
GILDGilead Sciences$88.63$81.77-7.74%Buy

BIIB Forecast FAQ

Is Biogen a good buy?

Yes, according to 33 Wall Street analysts, Biogen (BIIB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 24 'Buy' recommendations, accounting for 72.73% of BIIB's total ratings.

What is BIIB's price target?

Biogen (BIIB) average price target is $276.59 with a range of $202 to $400, implying a 77.30% from its last price of $156. The data is based on 33 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Biogen stock go up soon?

According to Wall Street analysts' prediction for BIIB stock, the company can go up by 77.30% (from the last price of $156 to the average price target of $276.59), up by 156.41% based on the highest stock price target, and up by 29.49% based on the lowest stock price target.

Can Biogen stock reach $200?

BIIB's average twelve months analyst stock price target of $276.59 supports the claim that Biogen can reach $200 in the near future.

What is Biogen's current price target trend?

5 Wall Street analysts forecast a $272.8 price target for Biogen (BIIB) this month, up 74.87% from its last price of $156. Compared to the last 3 and 12 months, the average price target increased by 60.34% and increased by 77.43%, respectively.

What are Biogen's analysts' financial forecasts?

Biogen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.52B (high $9.91B, low $9.1B), average EBITDA is $3.55B (high $3.69B, low $3.39B), average net income is $2.31B (high $2.6B, low $1.95B), average SG&A $2.08B (high $2.16B, low $1.98B), and average EPS is $15.82 (high $17.8, low $13.39). BIIB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.73B (high $10.09B, low $9.25B), average EBITDA is $3.63B (high $3.76B, low $3.45B), average net income is $2.11B (high $2.21B, low $1.97B), average SG&A $2.12B (high $2.2B, low $2.02B), and average EPS is $14.44 (high $15.13, low $13.51).

Did the BIIB's actual financial results beat the analysts' financial forecasts?

Based on Biogen's last annual report (Dec 2022), the company's revenue was $10.17B, beating the average analysts forecast of $9.89B by 2.89%. Apple's EBITDA was $2.69B, missing the average prediction of $3.58B by -25.00%. The company's net income was $3.05B, beating the average estimation of $1.95B by 55.88%. Apple's SG&A was $2.4B, missing the average forecast of $2.69B by -10.55%. Lastly, the company's EPS was $20.96, beating the average prediction of $16.02 by 30.88%. In terms of the last quarterly report (Sep 2023), Biogen's revenue was $2.53B, beating the average analysts' forecast of $2.4B by 5.44%. The company's EBITDA was $371.7M, missing the average prediction of $894.36M by -58.44%. Biogen's net income was $-68.1M, missing the average estimation of $579.74M by -111.75%. The company's SG&A was $788.2M, beating the average forecast of $523.35M by 50.61%. Lastly, the company's EPS was $-0.47, missing the average prediction of $3.97 by -111.83%